NCT05507567View on ClinicalTrials.gov

Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

August 12, 2022

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions
Influenza Viral Infections
Interventions
DRUG

Neumifil

Liquid for intranasal spray administration

DRUG

Placebo

Liquid for intranasal spray administration

Trial Locations (1)

E1 2AX

hVIVO Services Limited, London

Sponsors

Lead Sponsor

Pneumagen Ltd.
All Listed Sponsors
lead

Pneumagen Ltd.

INDUSTRY

NCT05507567 - Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model | Biotech Hunter | Biotech Hunter